

Supplementary Materials: CA-170 – a potent small-molecule PD-L1 inhibitor or not?

Bogdan Musielak, Justyna Kocik, Lukasz Skalniak, Katarzyna Magiera-Mularz, Dominik Sala, Mirosława Czub, Małgorzata Stec, Maciej Siedlar, Tad A. Holak and Jacek Plewka*




Figure S1. A) ^1H - ^{15}N HMQC spectra of apo-hPD-L1 (18-134) (blue) and hPD-L1 (18-134) with AUNP-12 (red) in the molar ratio 1/5. **B)** ^1H NMR spectra of apo-hPD-L1 (18-134) (blue), hPD-L1 (18-134) with AUNP-12 (red) in the molar ratio 1/5, apo-hPD-L1 (18-239) (purple), and hPD-L1 (18-239) with AUNP-12 (green) in the molar ratio 1/5.




Figure S2. **A)** ^1H - ^{15}N HMQC spectra of apo-hPD-1 (blue) and hPD-1 with **AUNP-12** (red) in the molar ratio 1/5. **B)** ^1H NMR spectra of apo- hPD-1 (blue), hPD-1 with **AUNP-12** (red) in the molar ratio 1/5.




Figure S3. ^1H NMR spectra of apo-hPD-L1 (18-134) (blue) and with **BMS-1166** compound (green) and **peptide-57** (red) in the molar ratio 1/1, respectively.